Kura Oncology Inc. (KURA) Financial Statements (2024 and earlier)

Company Profile

Business Address 12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments423,957,000437,985,000517,960,000633,320,000236,891,000178,985,000
Cash and cash equivalents37,318,00051,802,00090,672,000325,493,00026,135,00016,119,000
Short-term investments386,639,000386,183,000427,288,000307,827,000210,756,000162,866,000
Receivables     30,000224,000
Other undisclosed current assets8,524,0008,441,0004,329,0003,972,0002,682,0001,988,000
Total current assets:432,481,000446,426,000522,289,000637,292,000239,603,000181,197,000
Noncurrent Assets
Operating lease, right-of-use asset6,993,0003,842,0005,573,0006,334,000 
Property, plant and equipment1,859,0002,540,0002,673,0002,021,00044,000(92,000)
Restricted cash and investments  210,000210,000210,000  
Other noncurrent assets7,602,0003,288,0003,306,0001,355,0002,325,0001,182,000
Other undisclosed noncurrent assets      92,000
Total noncurrent assets:16,454,0009,880,00011,762,0009,920,0002,369,0001,182,000
TOTAL ASSETS:448,935,000456,306,000534,051,000647,212,000241,972,000182,379,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:33,757,00021,739,00022,455,00023,024,00015,314,00013,385,000
Employee-related liabilities7,923,0007,016,0003,694,0003,437,000
Accounts payable2,300,0001,533,0003,236,0002,753,0003,526,0003,890,000
Accrued liabilities14,455,00012,736,0001,073,0001,505,0001,124,000508,000
Other undisclosed accounts payable and accrued liabilities17,002,0007,470,00010,223,00011,750,0006,970,0005,550,000
Debt    3,000,000250,000 
Other undisclosed current liabilities1,506,0002,318,000   230,000
Total current liabilities:35,263,00024,057,00022,455,00026,024,00015,564,00013,615,000
Noncurrent Liabilities
Long-term debt and lease obligation9,332,0009,158,0004,612,0009,888,0007,250,0007,500,000
Long-term debt, excluding current maturities9,332,0009,158,000 4,250,0007,250,0007,500,000
Liabilities, other than long-term debt7,067,0002,813,000375,000395,000377,000279,000
Other liabilities705,000265,000375,000395,000377,000279,000
Operating lease, liability6,362,0002,548,0004,612,0005,638,000 
Total noncurrent liabilities:16,399,00011,971,0004,987,00010,283,0007,627,0007,779,000
Total liabilities:51,662,00036,028,00027,442,00036,307,00023,191,00021,394,000
Equity
Equity, attributable to parent397,273,000420,278,000506,609,000610,905,000218,781,000160,985,000
Common stock7,0007,0007,0007,0005,0004,000
Additional paid in capital1,119,976,000997,111,000941,359,000913,354,000431,322,000310,849,000
Accumulated other comprehensive income (loss)(1,271,000)(8,032,000)(1,789,000)46,000331,000(131,000)
Accumulated deficit(721,439,000)(568,808,000)(432,968,000)(302,502,000)(212,877,000)(149,737,000)
Total equity:397,273,000420,278,000506,609,000610,905,000218,781,000160,985,000
TOTAL LIABILITIES AND EQUITY:448,935,000456,306,000534,051,000647,212,000241,972,000182,379,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(165,804,000)(139,865,000)(131,258,000)(91,899,000)(67,479,000)(62,883,000)
Operating loss:(165,804,000)(139,865,000)(131,258,000)(91,899,000)(67,479,000)(62,883,000)
Nonoperating income13,173,0004,025,000792,0002,274,0004,339,0002,436,000
Interest and debt expense(1,549,000)(229,000)(212,000)(578,000)(580,000)(498,000)
Loss from continuing operations:(154,180,000)(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)
Loss before gain (loss) on sale of properties:(130,678,000)(90,203,000)(63,720,000)(60,945,000)
Net loss:(154,180,000)(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)
Other undisclosed net income attributable to parent1,549,000229,000212,000578,000580,000498,000
Net loss available to common stockholders, diluted:(152,631,000)(135,840,000)(130,466,000)(89,625,000)(63,140,000)(60,447,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(154,180,000)(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)
Other comprehensive income (loss)6,761,000(6,243,000)(1,835,000)(285,000)462,000(82,000)
Other undisclosed comprehensive income      
Comprehensive loss:(147,419,000)(142,312,000)(132,513,000)(90,488,000)(63,258,000)(61,027,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,549,000229,000212,000578,000580,000498,000
Comprehensive loss, net of tax, attributable to parent:(145,870,000)(142,083,000)(132,301,000)(89,910,000)(62,678,000)(60,529,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: